NASDAQ:XCUR

Exicure Stock Insider Trading

Healthcare > Biotechnology

Buy XCUR

*Your capital is at risk

$3.16

+0.0500 (+1.61%)

At Close: Jun 03, 2026

Exicure Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -28.38. In total, the insiders bought 13.39M and sold 26.65M XCUR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-28.38
● Buy	13.39M shares
● Sell	26.65M shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jan 16, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -28.38. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 27, 2023 Buy	Common Stock J-Other	Shin Seung Soo	Director	0 Value: $0
Feb 27, 2023 Buy	Common Stock J-Other	Jo Cheolho	Director	0 Value: $0
Feb 27, 2023 Buy	Common Stock J-Other	Jo Cheolho	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Ahn Changil	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Sung Uh Kang Paul	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Lee Hyukku	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Lee Hyukku	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Sung Uh Kang Paul	Director	0 Value: $0
Feb 24, 2023 Buy	Common Stock J-Other	Ahn Changil	Director	0 Value: $0
Feb 22, 2023 Sell	CBI USA, Inc. 1st Bearer-type Interest Unsecured Private J-Other	Cbi Usa, Inc. 10 Percent Owner	10% Owner	5 440 000 Value: $8.70M
Feb 22, 2023 Sell	CBI USA, Inc. 1st Bearer-type Interest Unsecured Private J-Other	Cbi Usa, Inc. 10 Percent Owner	10% Owner	5 440 000 Value: $8.70M
Jan 04, 2023 Buy	Stock Option (right to buy) A-Award	Hwang Jiyoung Director	Director	10 000 Value: $0
Jan 04, 2023 Buy	Stock Option (right to buy) A-Award	Hwang Jiyoung Director	Director	10 000 Value: $0
Dec 30, 2022 Buy	Common Stock J-Other	Hwang Jiyoung Insider	Unknown	0 Value: $0
Dec 30, 2022 Buy	Common Stock J-Other	Hwang Jiyoung	Director	0 Value: $0
Dec 30, 2022 Buy	Common Stock J-Other	Hwang Jiyoung	Director	0 Value: $0
Dec 30, 2022 Buy	Common Stock J-Other	Hwang Jiyoung Insider	Unknown	0 Value: $0
Dec 15, 2022 Buy	Common Stock P-Purchase	Cbi Usa, Inc. Director	Director	3 400 000 Value: $5.44M
Dec 15, 2022 Buy	Common Stock P-Purchase	Cbi Usa, Inc. Director	Director	3 400 000 Value: $5.44M
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Muralidhar Bali	Director	50 000 Value: $0
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Cleland Jeffrey L Director	Director	50 000 Value: $6K
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Cleland Jeffrey L	Director	50 000 Value: $0
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Sulat James R Director	Director	50 000 Value: $6K
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Sulat James R	Director	50 000 Value: $0
Jun 13, 2022 Buy	Employee Stock Option (right to buy) A-Award	Garofalo Elizabeth A. Director	Director	50 000 Value: $6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EXICURE, INC.

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S...

Read Full Profile Here